BRPI0924460A2 - composição farmacêutica para uso em oftalmologia médica e veterinária - Google Patents

composição farmacêutica para uso em oftalmologia médica e veterinária

Info

Publication number
BRPI0924460A2
BRPI0924460A2 BRPI0924460-3A BRPI0924460A BRPI0924460A2 BR PI0924460 A2 BRPI0924460 A2 BR PI0924460A2 BR PI0924460 A BRPI0924460 A BR PI0924460A BR PI0924460 A2 BRPI0924460 A2 BR PI0924460A2
Authority
BR
Brazil
Prior art keywords
medical
pharmaceutical composition
veterinary ophthalmology
ophthalmology
veterinary
Prior art date
Application number
BRPI0924460-3A
Other languages
English (en)
Inventor
Maxim Vladimirovich Skulachev
Original Assignee
Obschestvo S Ogranichennoi Otvetstvennostyu '"Mitorekh"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obschestvo S Ogranichennoi Otvetstvennostyu '"Mitorekh" filed Critical Obschestvo S Ogranichennoi Otvetstvennostyu '"Mitorekh"
Publication of BRPI0924460A2 publication Critical patent/BRPI0924460A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0924460-3A 2009-06-10 2009-06-10 composição farmacêutica para uso em oftalmologia médica e veterinária BRPI0924460A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU2009/000295 WO2010143990A1 (ru) 2009-06-10 2009-06-10 Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии

Publications (1)

Publication Number Publication Date
BRPI0924460A2 true BRPI0924460A2 (pt) 2018-03-27

Family

ID=43309061

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924460-3A BRPI0924460A2 (pt) 2009-06-10 2009-06-10 composição farmacêutica para uso em oftalmologia médica e veterinária

Country Status (15)

Country Link
US (2) US9724313B2 (pt)
EP (2) EP2823814A1 (pt)
JP (1) JP5659388B2 (pt)
KR (1) KR101478728B1 (pt)
CN (2) CN102548548B (pt)
AU (1) AU2009347921B8 (pt)
BR (1) BRPI0924460A2 (pt)
CA (1) CA2764481C (pt)
EA (1) EA025414B1 (pt)
ES (1) ES2527791T3 (pt)
IL (1) IL216702A0 (pt)
MX (1) MX2011013150A (pt)
UA (1) UA104320C2 (pt)
WO (1) WO2010143990A1 (pt)
ZA (1) ZA201200111B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704064T3 (es) * 2011-06-03 2019-03-14 Mitotech Sa Formulaciones orales de antioxidantes dirigidos mitocondrialmente y su preparación y uso
CN102327650B (zh) * 2011-08-25 2014-01-22 高家旗 一种人工晶状体植入手术柔性水溶胶辅剂及其制备方法
RU2506086C1 (ru) * 2012-09-07 2014-02-10 Илья Александрович Марков Глазные капли, обладающие противовоспалительным и антибактериальным действием
EP3827823A1 (en) * 2012-12-19 2021-06-02 Novartis AG Lfa-1 inhibitor formulations
RU2510264C1 (ru) * 2012-12-21 2014-03-27 Станислав Анатольевич Кедик Офтальмологический препарат в виде глазных капель, содержащий разветвленные полигексаметиленгуанидины
CN103405766B (zh) * 2013-08-06 2016-01-06 温州医学院眼视光研究院 一种贝伐单抗滴眼液及其制备方法
US9308165B2 (en) * 2013-08-22 2016-04-12 Therapeutic Vision, Inc. Composition for treating ocular effects of diabetes
US9844537B2 (en) 2013-08-28 2017-12-19 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US11179327B2 (en) 2013-08-28 2021-11-23 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
US10307408B2 (en) 2013-08-28 2019-06-04 Presbyopia Therapies, LLC Contact lens compositions and methods for the treatment of presbyopia
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US10064818B2 (en) 2013-08-28 2018-09-04 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US10617763B2 (en) 2013-08-28 2020-04-14 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US9833441B2 (en) 2013-08-28 2017-12-05 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
RU2528912C1 (ru) * 2013-10-09 2014-09-20 Станислав Анатольевич Кедик Глазные капли на основе композиции фармацевтически приемлемой аддитивной соли кислоты и метилэтилпиридинола, содержащие композицию витаминов группы в
RU2533276C1 (ru) * 2013-10-09 2014-11-20 Станислав Анатольевич Кедик Глазные капли на основе композиции фармацевтически приемлемой аддитивной соли кислоты и метилэтилпиридинола и таурина, содержащие композицию витаминов группы в
EP3116470B1 (en) * 2014-02-25 2019-05-08 Mitotech SA Cosmetic compositions of mitochondrially targeted antioxidants
US20170128467A1 (en) * 2014-05-30 2017-05-11 Friehoff Lawrence T Antimicrobial pharmaceutical compositions with multiple drug resistance inhibiting properties
WO2016013993A1 (en) * 2014-07-25 2016-01-28 Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. Stable preservative free ophthalmic formulations of opioid antagonists
WO2016200364A1 (en) * 2015-06-08 2016-12-15 Stealth Peptides International, Inc. THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF
US12653779B2 (en) 2015-06-18 2026-06-16 Lenz Therapeutics Operations, Inc. Compositions and methods for the treatment of presbyopia
CN107312194A (zh) * 2017-07-13 2017-11-03 温州嘉泰乳胶制品有限公司 乳胶固化配方工艺
US20190321334A1 (en) * 2018-04-19 2019-10-24 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
CN111351886B (zh) * 2018-12-24 2023-06-23 成都平和安康医药科技有限公司 一种测定酚磺乙胺药物中含有的杂质及其主药含量的方法
EP4072512A4 (en) * 2019-12-10 2024-01-10 Mitotech S.A. POLYMER MATRICES FOR VARIOUS COMPOSITIONS OF MITOCHONDRIALLY DIRECTED ANTIOXIDANTS
JP2023520698A (ja) * 2020-04-03 2023-05-18 ミトテック ソシエテ アノニム 重度の炎症状態を処置するためのミトコンドリア標的抗酸化物質の使用
RU2768752C1 (ru) * 2020-12-24 2022-03-24 Общество с ограниченной ответственностью "Международная лаборатория "Резистом" Противовирусная композиция для защиты растений на основе поли(а):поли(у)
WO2023091439A1 (en) 2021-11-17 2023-05-25 Lenz Therapeutics, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
US11648247B1 (en) 2021-12-16 2023-05-16 Lenz Therapeutics, Inc. Compositions and methods for the treatment of presbyopia
CN116270630A (zh) * 2023-04-03 2023-06-23 爱尔眼科医院集团股份有限公司 巴马汀在制备治疗眼部疾病的药物中的用途
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07252149A (ja) * 1994-01-27 1995-10-03 Senju Pharmaceut Co Ltd 眼科用剤
US5538974A (en) * 1994-01-27 1996-07-23 Senju Pharamceutical Co., Ltd. Ophthalmic composition for lowering intraocular pressure
US5535974A (en) * 1994-03-07 1996-07-16 Savitski; Richard H. Scaffold bracket
CN1318434C (zh) 1997-11-25 2007-05-30 安迪珀蒂恩生物工艺学有限公司 线粒体靶向的抗氧剂
US6331532B1 (en) 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
US20070270381A1 (en) 2000-05-25 2007-11-22 Antipodean Pharmaceuticals, Inc. Mitochondrially targeted antioxidants
US20080275005A1 (en) 1998-11-25 2008-11-06 Murphy Michael P Mitochondrially targeted antioxidants
JP2001172183A (ja) * 1999-12-21 2001-06-26 Wakamoto Pharmaceut Co Ltd 眼科用医薬組成物
US20020044913A1 (en) 2000-02-11 2002-04-18 Hamilton Nathan D. Cosmetics to support skin metabolism
JP4859283B2 (ja) * 2001-05-23 2012-01-25 学校法人近畿大学 高安定性抗白内障医薬組成物
ITRM20010755A1 (it) 2001-12-20 2003-06-20 Simonelli Giuseppe Uso del chinone q10 per il trattamento delle malattie oculari.
CA2397684A1 (en) 2002-08-12 2004-02-12 Michael P. Murphy Mitochondrially targeted antioxidants
KR101003960B1 (ko) * 2003-08-22 2010-12-30 안티포딘 파마슈티칼스, 인코포레이티드 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체를 포함하는 약제학적 조성물
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
AU2005261654A1 (en) 2004-07-13 2006-01-19 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
KR20070057218A (ko) 2004-08-30 2007-06-04 가부시키가이샤 가네카 미토콘드리아 활성화제
RU2318500C2 (ru) 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
EA200900582A1 (ru) * 2006-10-20 2009-08-28 Общество С Ограниченной Ответственностью "Митотехнология" Фармацевтические композиции для профилактики и лечения глазных патологий
US8518915B2 (en) 2007-06-29 2013-08-27 Mitotech Sa Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases
JP2009091175A (ja) * 2007-10-04 2009-04-30 Sumitomo Electric Ind Ltd GaNエピタキシャル基板、半導体デバイス、GaNエピタキシャル基板及び半導体デバイスの製造方法
EP2303824B1 (en) 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EA201101576A1 (ru) * 2009-04-28 2012-04-30 Эдисон Фармасьютикалз, Инк. Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний

Also Published As

Publication number Publication date
US10213392B2 (en) 2019-02-26
EP2441453A4 (en) 2013-04-10
ZA201200111B (en) 2012-09-26
EA201101518A1 (ru) 2012-04-30
KR20130082069A (ko) 2013-07-18
JP2012529504A (ja) 2012-11-22
ES2527791T3 (es) 2015-01-29
EA025414B1 (ru) 2016-12-30
IL216702A0 (en) 2012-02-29
EP2441453B1 (en) 2014-11-26
CN102548548A (zh) 2012-07-04
US20120094962A1 (en) 2012-04-19
CN107362157B (zh) 2022-08-26
CN102548548B (zh) 2017-09-01
AU2009347921A1 (en) 2012-01-19
KR101478728B1 (ko) 2015-01-02
US9724313B2 (en) 2017-08-08
CN107362157A (zh) 2017-11-21
UA104320C2 (ru) 2014-01-27
EP2823814A1 (en) 2015-01-14
US20170304225A1 (en) 2017-10-26
AU2009347921B2 (en) 2014-07-17
CA2764481C (en) 2015-11-24
EP2441453A1 (en) 2012-04-18
WO2010143990A1 (ru) 2010-12-16
MX2011013150A (es) 2012-03-14
CA2764481A1 (en) 2010-12-16
AU2009347921B8 (en) 2014-07-24
JP5659388B2 (ja) 2015-01-28

Similar Documents

Publication Publication Date Title
MX2011013150A (es) Composicion farmaceutica para uso en oftalmologia medica y veterinaria.
UY30373A1 (es) Derivados de fenilalanina, procedimientos de preparacion y aplicaciones
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
BR112015007814A2 (pt) diagnóstico, prevenção e tratamento de doenças da articulação
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
EP3501546A3 (de) Cystein-wirkstoff konjugate und ihre verwendung
CU24065B1 (es) Forma de dosificación farmacéutica que comprende nifedipino y un antagonista de angiotensina ii
WO2011116139A3 (en) Improved pharmaceutical compositions comprising cck- 8 and methods of delivery
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations
MX340985B (es) Compuestos de n-heteroarilo.
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
CR20110704A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amilodipina, su preparación y su aplicación terapéutica
WO2012158405A3 (en) Compositions and methods for the treatment of skin diseases
WO2011091000A3 (en) Oral care compositions and methods
EA201170108A1 (ru) Сосательная композиция для лечения воспалительных заболеваний полости рта и глотки
WO2008043788A3 (en) Novel compounds
IL217519A (en) Tazarotene derivatives, pharmaceutical compositions comprising them and use thereof for the manufacture of medicaments for the treatment of skin disorders
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
BRPI1009003A2 (pt) "método para expressão recombinante de um ccn1 humano, uso de um ccn1 humano, anticorpo contra ccn1 humano, uso de um anticorpo contra ccn1 humano, método para a fabricação de um medicamento para o tratamento de doenças e composição farmacêutica"

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]